• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 215

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Erica Rex: Scientific Integrity, Psychedelic Research, and the Religious Leader Study

Pα+ Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD; Longevity Crowd Hypes Psilocybin Study; Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch?

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on Psychedelic Science, AI, and Idealist Monism

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

Filament Health Shares to Commence Trading on the OTC Market

Mydecine Innovations Group Announces MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical...

PT261 – Dr. Tiago Reis Marques – Ketamine, New Drugs, and...

Psychedelic Bulletin: DEA Proposes Increase to Psilocybin Quota; Field Trip Launches...

PTSF75 – Possession Limits, Religion, and Scalability

Glow Time: PsychLight Brings a Powerful Tool to Psychedelic Research

Red Light Closes Acquisition of Mera Life Sciences and Files Quarterly...

Distinguished Psychedelic Researcher, Professor of Psychiatry and Neuroscience, Rachel Yehuda, PhD,...

Red Light Holland Successfully Completes Canada’s Largest Legal Sale and Import...

MINDCURE Announces Financial Results for Fiscal 2021

1...214215216...292Page 215 of 292

EDITOR PICKS

Erica Rex: Scientific Integrity, Psychedelic Research, and the Religious Leader Study

Pα+ Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD;...

Psychedelic Funding Update: Q2 2025

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©